300 related articles for article (PubMed ID: 30430883)
21. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for oocyte retrieval failure in controlled ovarian hyperstimulation protocols: a retrospective observational cohort study.
Hasegawa A; Takahashi T; Igarashi H; Amita M; Matsukawa J; Nagase S
Reprod Biol Endocrinol; 2015 Jun; 13():53. PubMed ID: 26033112
[TBL] [Abstract][Full Text] [Related]
23. The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol.
Geng Y; Lai Q; Xun Y; Jin L
Int J Gynaecol Obstet; 2018 Jul; 142(1):97-103. PubMed ID: 29542120
[TBL] [Abstract][Full Text] [Related]
24. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
25. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
26. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
27. Impact of growth hormone on IVF/ICSI outcomes and endometrial receptivity of patients undergoing GnRH antagonist protocol with fresh embryo transfer: a pilot study.
Chu Y; Wang L; Xie J; Yang S; Liu S; Hu D; Yue J
Front Endocrinol (Lausanne); 2023; 14():1225121. PubMed ID: 37727454
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
29. Does the estradiol level on the day of human chorionic gonadotropin administration predict the clinical outcome of controlled ovarian hyperstimulation?
Erzincan SG; Esmer AC; Baysal B
Clin Exp Obstet Gynecol; 2014; 41(6):709-12. PubMed ID: 25551969
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders.
Zhou X; Guo P; Chen X; Ye D; Liu Y; Chen S
Int J Gynaecol Obstet; 2018 Jun; 141(3):327-331. PubMed ID: 29388691
[TBL] [Abstract][Full Text] [Related]
31. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
[TBL] [Abstract][Full Text] [Related]
32. Gonadotrophin-releasing hormone antagonists for assisted conception.
Al-Inany H; Aboulghar M
Cochrane Database Syst Rev; 2001; (4):CD001750. PubMed ID: 11687120
[TBL] [Abstract][Full Text] [Related]
33. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
34. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
35. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
36. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
[TBL] [Abstract][Full Text] [Related]
37. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
38. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
39. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
[TBL] [Abstract][Full Text] [Related]
40. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
